Nyxoah S.A. (NASDAQ:NYXH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Nyxoah S.A. (NASDAQ:NYXH) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $17.80.

Several brokerages have commented on NYXH. Cantor Fitzgerald lowered their price objective on shares of Nyxoah from $18.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, May 15th. HC Wainwright lowered their price objective on Nyxoah from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, May 24th. Oppenheimer cut their price target on shares of Nyxoah from $20.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, May 15th. Stifel Nicolaus decreased their price objective on Nyxoah from $27.00 to $19.00 and set a “buy” rating for the company in a report on Monday, June 24th. Finally, Piper Sandler lifted their target price on Nyxoah from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, March 6th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC purchased a new position in Nyxoah S.A. (NASDAQ:NYXH) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 50,699 shares of the company’s stock, valued at approximately $684,000.

Nyxoah Stock Performance

NYXH opened at $6.97 on Wednesday. The stock has a fifty day moving average of $9.12 and a 200-day moving average of $9.86. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.94 and a quick ratio of 3.70.

Nyxoah (NASDAQ:NYXH) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.45). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.20 million. On average, research analysts forecast that Nyxoah will post -1.72 EPS for the current year.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.